MOLN
Closed
Molecular Partners Ag Adr
3.71
-0.11 (-2.88%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 3.82
Day's Range: 3.71 - 3.84
Send
sign up or login to leave a comment!
When Written:
6.2273
Molecular Partners AG is a Swiss biopharmaceutical company that specializes in the development of innovative therapeutic proteins for the treatment of serious diseases. The company's proprietary technology platform, called DARPin, allows the design and engineering of highly specific and potent protein therapeutics with a broad range of applications in oncology, ophthalmology, and immunology.
Molecular Partners AG is listed on the SIX Swiss Exchange and also has American Depositary Receipts (ADRs) that trade on the OTCQX market in the United States under the ticker symbol MOLN. Each ADR represents one ordinary share of the company.
As of August 2021, Molecular Partners AG had a market capitalization of approximately CHF 1.1 billion ($1.2 billion) and a pipeline of several product candidates in various stages of clinical development, including MP0250, a novel immuno-oncology drug for the treatment of solid tumors, and MP0274, a treatment for wet age-related macular degeneration. The company has also entered into partnerships with several leading pharmaceutical companies, including Amgen, Novartis, and Allergan.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Molecular Partners AG is listed on the SIX Swiss Exchange and also has American Depositary Receipts (ADRs) that trade on the OTCQX market in the United States under the ticker symbol MOLN. Each ADR represents one ordinary share of the company.
As of August 2021, Molecular Partners AG had a market capitalization of approximately CHF 1.1 billion ($1.2 billion) and a pipeline of several product candidates in various stages of clinical development, including MP0250, a novel immuno-oncology drug for the treatment of solid tumors, and MP0274, a treatment for wet age-related macular degeneration. The company has also entered into partnerships with several leading pharmaceutical companies, including Amgen, Novartis, and Allergan.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!